<DOC>
	<DOCNO>NCT00813449</DOCNO>
	<brief_summary>Multicenter , double-blinding , randomize control , phase II clinical trial combine chemotherapy Endostar ( Recombinant Human Endostatin ) untreated patient advanced melanoma , To compare efficacy safety Endostar combine Dacarbazine monotherapy Dacarbazine advance melanoma</brief_summary>
	<brief_title>Safety Study Combined Chemotherapy Endostar Untreated Patients With Advanced Melanoma</brief_title>
	<detailed_description>Dacarbazine ( DTIC ) approve treat metastatic melanoma 1970s , single agent give response rate 20 % . There effort ameliorate poor result use DTIC different combination without significant improvement . In addition , new study melanoma cell vitro show DTIC combination Endostar , suggest potential clinical benefit concomitant treatment DTIC antiangiogenesis therapy . Endostar wild spectrum safe antiangiogenesis factor could suppress almost 65 kind tumor mass animal model affect 12 percent human genome . The purpose study determine whether combination therapy endostar DTIC safe increase response rate progression-free survival patient ( pt ) metastatic melanoma . We evaluate efficacy safety Endostar plus DTIC hope provide new hope advance melanoma patient .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>1 . Age &gt; 18 year old , males female ; 2 . Untreated patient advanced melanoma confirm histopathology cytology ; 3 . With tumor focus evaluate CT MRI ; least one diameter ≥ 1 cm ( include metastatic lymph node , diameter ≥ 1 cm confirm CT scan ) ; superficial focus ≥ 2 cm ( confirm photo calibration ) ; 4 . No contraindication chemotherapy , normal peripheral hemogram , renal hepatic function : Peripheral hemogram : WBC≥4.0×109/L，PLT≥80×109/L，Hgb≥90g/L； Renal function : serum BUN creatinine ≤2.5×UNL ; Hepatic function : transaminase≤2.5×UNL , ≤5×UNL patient liver metastasis ; 5 . Karnofsky performance scale≥70 ( appendix 1 ) ; expect survival time≥3 month ; 6 . Patients voluntary participate sign inform content . 1 . Pregnant breastfeeding female ; female reproductive ability take contraception method ; 2 . With severe acute infection uncontrolled ; purulent chronic infection wound difficult recover ; 3 . With history severe heart disease , include congestive heart failure , uncontrolled arrhythmia high risk , unstable angina pectoris , myocardial infarction , severe cardiac valvular disease refractory hypertension ; 4 . Have treat dacarbazine dacarbazine include combination chemotherapy ; 5 . Patients uncontrolled neurological , mental disease psychosis , patient poor compliance coordinate therapy describe treatment response ; 6 . Uncontrolled brain metastasis patient obvious manifestation intracranial hypertension neurological mental disorder ; 7 . Allergic drug trial ; 8 . Patients second tumor ; 9 . Patients participate clinical trial ; 10 . Other condition regard exclusion trialists</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Endostar</keyword>
	<keyword>advanced melanoma</keyword>
	<keyword>combine chemotherapy</keyword>
</DOC>